OTHER SUCESSFUL BIOTECH WITH NICE BUYOUTS
Someone on here was asking about other biotech's that had successful outcomes for the shareholders.
One such case that I think could be pretty close example for what could be for CVBT was, the company that was brought to my attention was AveXis.
They originally were based in Dallas, that’s where their founders were from. I know from a friend of a friend that one of the founders of AveXis is best buddies with one of the CVBT directors.
AveXis did their IPO with Goldman Sachs in 2016 at $20 per share.
They address a rare disease which has a patient population of less that 50,000 p.a. in USA. They had one patent, one therapy. However when the FDA saw the results from a handful of patients, they took them from Phase 1 to Phase 3.
On that news the share price went from $20 to $75. In May 2018 Novartis bought them for $218 per share of $8.7 billion in cash!!
One patent, one therapy, small patient population and; big pharma pays over $8 billion. In that case what is CVBT’s intrinsic value???
LETS ALL HOPE SOMETHING SIMILAR HAPPENS WITH CVBT!
